Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.

Date publication

janvier 2024

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr ZANETTA Sylvie , Dr MAYEUR Didier , Dr GALLAND Loïck

Tous les auteurs :
Baude J, Niogret J, Jacob P, Bardet F, Desmoulins I, Zanetta S, Kaderbhai C, Galland L, Mayeur D, Delattre B, Cormier L, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38254771

Résumé

Chemotherapy using carboplatin and etoposide (CE) is frequently pragmatically proposed to treat metastatic prostate cancer (mPC), both primary small-cell neuroendocrine (PSC-NE) carcinoma and adenocarcinoma with or without neuroendocrine (NE) marker elevation. However, the real benefit of CE is poorly reported in the recent therapeutic context.

Mots clés

NSE, PSA, anaplastic, carboplatin, chromogranin, etoposide, neuroendocrine, prostate cancer, survival

Référence

Cancers (Basel). 2024 01 9;16(2):